Hookipa rises as FDA clears marketing application for its HIV vaccine

Hookipa Pharma

20/11/2023 13:42

** Shares of therapy developer Hookipa Pharma  HOOK.O  rise
~4% to 54 cents premarket
    ** Co says the U.S. FDA cleared the marketing application
for HB-500, HOOK's HIV vaccine developed in collaboration with
Gilead Sciences  GILD.O  
    ** Adds early-stage trial to start in the first half of 2024
    ** HIV (human immunodeficiency virus) is a virus, which
attacks cells that help the body fight infection
    ** Up to last close, stock down 35.9% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))